Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 55 for leukemia

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

    Jacksonville, FL

  2. A Study to Evaluate Acalabrutinib With or Without Obinutuzumab to Treat Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study of ONO-7475 in Patients With Acute Leukemias

    Jacksonville, FL

  4. Global Trial in APG2575 for Patients With CLL/​SLL

    Jacksonville, FL

  5. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma

    Rochester, MN, Scottsdale/Phoenix, AZ

  6. Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

    Rochester, MN

  7. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib to To Treat Newly-diagnosed AML with or without FLT3 Mutations

    Rochester, MN

  8. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation

    Rochester, MN

  9. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis

    Scottsdale/Phoenix, AZ

  10. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

    Rochester, MN

.

Mayo Clinic Footer